Cancer Drug Safety and Public Health Policy : A Changing Landscape (Cancer Treatment and Research 184) (1st ed. 2022. 2023. xi, 167 S. XI, 167 p. 16 illus., 10 illus. in colo)

個数:

Cancer Drug Safety and Public Health Policy : A Changing Landscape (Cancer Treatment and Research 184) (1st ed. 2022. 2023. xi, 167 S. XI, 167 p. 16 illus., 10 illus. in colo)

  • 在庫がございません。海外の書籍取次会社を通じて出版社等からお取り寄せいたします。
    通常6~9週間ほどで発送の見込みですが、商品によってはさらに時間がかかることもございます。
    重要ご説明事項
    1. 納期遅延や、ご入手不能となる場合がございます。
    2. 複数冊ご注文の場合、分割発送となる場合がございます。
    3. 美品のご指定は承りかねます。
  • 【入荷遅延について】
    世界情勢の影響により、海外からお取り寄せとなる洋書・洋古書の入荷が、表示している標準的な納期よりも遅延する場合がございます。
    おそれいりますが、あらかじめご了承くださいますようお願い申し上げます。
  • ◆画像の表紙や帯等は実物とは異なる場合があります。
  • ◆ウェブストアでの洋書販売価格は、弊社店舗等での販売価格とは異なります。
    また、洋書販売価格は、ご注文確定時点での日本円価格となります。
    ご注文確定後に、同じ洋書の販売価格が変動しても、それは反映されません。
  • 製本 Paperback:紙装版/ペーパーバック版/ページ数 167 p.
  • 言語 ENG
  • 商品コード 9783031044045

Full Description

This book offers a wide-ranging description and analysis of recent developments and current trends in health policy with regard to cancer drug safety. The book opens with an overview of pharmacovigilance for cancer blockbuster drugs, covering both general considerations and efforts to develop a structured framework for the identification and reporting of adverse drug reactions (ADRs). A number of important examples of serious ADRs to hematology and oncology drugs are then reviewed, with evaluation of the lessons learned and the policy implications of the ensuing legal cases and their settlements. Further, the difficulty of reporting such blockbuster side effects in the medical literature is explored in an empirical study. Significant advances have been achieved in analytic methods for the identification of ADRs, and here there is a particular focus on the value of optimal discriminant analysis. Finally, the impacts on pharmacovigilance and drug safety of the huge fines paid under the U.S. False Claims Act relating to the defrauding of governmental programs also receive careful attention - these fines are playing an important role in changing the landscape for pharmaceutical safety.

Contents

Fluoroquinolone-Associated Disability and Other Fluoroquinolone Associated Serious Adverse Events: Unexpected Toxicities Have Emerged in Recent Years.- Biosimilar Epoetin in the United States: A View from the Southern Network on Adverse Reactions.- Policing of Drug Safety Information under the False Claims Act.- Translating Research Into Health Policy: The Citizen Petition Experience with the Food and Drug Administration.- Systemic Barriers and Potential Concerns from Reporting Serious Adverse Drug Reactions.- Was there Something Rotten in Denmark: Nephrogenic System Fibrosis Cases Occuring in Copenhagen.- Rituximab-associated Progressive Multifocal Leukoencephalopathy: A fatal adverse drug reaction.- Maximum Accuracy Machine Learning Statistical Analysis - A Novel Approach.- Investigating Severe Adverse Reactions: Examples of the ANTICIPATE Methodology at Work.- Consequences to patients, clinicians, and manufacturers when very serious adverse drug reactions are identified (1997-2019):A qualitative analysis from the Southern Network on Adverse Reactions (SONAR).- Moderna, Pfizer-BioNTech, and Johnson & Johnson/Janssen Post-Covid Vaccine Hematological Adverse Events Including Cerebral Venous Sinus Thrombosis (CVST), Thrombotic Thrombocytopenia (VITT), Blood Clots, Increased Vaginal/Menstrual Bleeding and/or Miscarriage, Stillbirth Delivery, or Premature Birth.- Investigating Novel Genetic Fluoroquinolone Associated Disorders.